TKD 004
Alternative Names: TKD-004Latest Information Update: 20 Dec 2023
At a glance
- Originator Therakind
- Class Antihypoglycaemics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Hypoglycaemia
Most Recent Events
- 20 Dec 2023 TKD 004 is available for licensing as of 20 Dec 2023. https://www.therakind.com/about-us (Therakind website, December 2023)
- 20 Dec 2023 Clinical trials in Hypoglycaemia in United Kingdom (Intranasal) (Therakind pipeline, December 2023)
- 19 Dec 2023 Preclinical trials in Hypoglycaemia in United Kingdom (Intranasal), prior to December 2023 (Therakind pipeline, December 2023)